SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
A Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Characteristics of SG301 SC Injection in Single-dose Healthy Subjects and Multiple-dose Systemic Lupus Erythematosus (SLE) Subjects
Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Listed as NCT06144710, this PHASE1 trial focuses on Systemic Lupus Erythematosus (SLE) and remains ongoing. Sponsored by Hangzhou Sumgen Biotech Co., Ltd., it has been updated 8 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
8 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2025 — Mar 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Mar 2024 [monthly]
Recruiting PHASE1
First recorded
Nov 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hangzhou Sumgen Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Bengbu, China
- • Fuzhou, China
- • Hangzhou, China
- • Jinan, China
- • Jining, China
- • Nanchang, China
- • Pingxiang, China
- • Shanghai, China
- • Shenzhen, China
- • Xiamen, China